Saturday 7 November 2026 Export ABVC’s income statement to Excel — free account

ABVC BioPharma, Inc.

ABVC Healthcare Biotechnology

ABVC BioPharma, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $509,600.00, up 234.4% from fiscal 2023.

Revenue: +66,233.3%
EPS: +76.9%
Free cash flow: +72.7%

Quarter to June 2026, against a year earlier

0.97 0.00 0.00%

Follow ABVC

Alert me

Market cap: $25.9M
P/E: 0.0×
Fwd P/E: −1.6×
Dividend yield: —
F-score: 6/9
Altman Z: −14.88
Beneish M: −3.98
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 16.08%

Capital & Financial Ratios $m

Size

Market Cap 25.92

Revenue ttm 1.30

Net income ttm (7.60)

Free cash flow ttm (2.69)

Net debt Q (0.09)

Valuation

P/E 0.00

Forward P/E (1.59)

Price / sales 19.38

Forward P/S Powerpack

Price / FCF 0.00

Price / book 2.06

Financial health

Current ratio Q 0.07

Debt / equity Q 0.00

Interest coverage Q (18.43)

Growth

Revenue growth Q +66,233.33%

Operating income growth Q +66.03%

EPS, this year —

EPS, next year A —

Revenue, next year A +718.29%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 13.90%

10-year low 10-year high

P/B against its own 10 years 20.98%

10-year low 10-year high

EV/Sales against its own 10 years 12.67%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	1	1	0
Receivables	1	1	—	—
Inventory	—	—	—	—
Other	1	1	1	0
	2	2	3	0

	2023	2024	2025	Q'26
Payables	—	—	—	—
ST’ Debt	—	—	—	—
Other	0	0	0	0
	6	7	6	6

Compound Annual Growth %

	10y	5y	3y
Sales	—	(6.20%)	12.72%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	37.95%	60.17%

Earnings Trends EPS, adjusted, against the consensus

Q1 FY23 Estimate −0.50 Actual −0.60

−2.22 −1.74 −1.25 −0.76 −0.27

Q2 FY22 Beat +1.40

Q3 FY22 Beat +0.90

Q4 FY22 Beat +0.40

Q1 FY23 Miss −0.10

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY22	−2.00	−0.60	Beat by 1.40
Q3 FY22	−2.00	−1.10	Beat by 0.90
Q4 FY22	−1.90	−1.50	Beat by 0.40
Q1 FY23	−0.50	−0.60	Miss by 0.10

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.06)	(0.03)	—	—	—
’25	(0.06)	(0.13)	(0.09)	(0.16)	(0.39)
’24	(0.30)	(0.09)	(0.04)	(0.06)	(0.42)
’23	(0.60)	(0.68)	(0.82)	(0.06)	(1.80)
’22	(2.00)	(0.60)	(1.10)	(1.50)	(5.20)
’21	(0.49)	(0.80)	(0.70)	(3.10)	(5.10)
’20	(0.60)	(0.90)	(0.90)	(2.49)	(5.37)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	1	—	—
’24	0	0	0	0	1
’23	0	0	0	0	0
’22	0	0	0	1	1
’21	0	0	0	0	0
’20	0	0	0	0	0
’19	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(1)	(1)	(1)	(1)	(3)
’24	(1)	0	0	(1)	(2)
’23	(1)	(1)	(1)	0	(4)
’22	(3)	(3)	(1)	0	(7)
’21	(1)	(1)	(2)	(3)	(8)
’20	(1)	(1)	0	(2)	(5)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(1)	(1)	(1)	(1)	(3)
’24	(1)	0	0	(1)	(2)
’23	(1)	(1)	(1)	0	(4)
’22	(3)	(3)	(1)	0	(8)
’21	(1)	(1)	(2)	(3)	(8)
’20	(1)	(1)	0	(2)	(5)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	0	1	0	0	1	0	1	—	1		+104.3%	—	—	—	—
	Gross margin, %	0.00	—	(2,547.14)	97.14	96.13	98.57	70.47	(98.16)	99.84	—	99.97		+99.8 pt	Powerpack ABVC BioPharma, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(11)	(4)	(6)	(4)	(11)	(11)	(16)	(8)	(5)	(8)	(8)		(3.0%)
	EBT margin, %	0.00	0.00	(91,851.43)	(571.51)	(2,238.90)	(3,150.87)	(1,599.77)	(5,265.62)	(1,053.69)	0.00	0.00		0.0 pt
	Net income	(11)	(4)	(6)	(4)	(11)	(12)	(16)	(8)	(5)	(8)	(8)		(3.0%)
Per share, $
Per share, $	Revenue	0.00	0.00	0.01	0.40	0.25	0.14	0.31	0.04	0.04	0.00	0.00		n/m
	Earnings	(1.08)	(3.58)	(5.22)	(2.10)	(4.63)	(5.10)	(5.20)	(1.91)	(0.42)	(0.39)	(0.34)		(10.7%)
	Cash flow	(0.32)	(1.25)	(0.78)	(1.79)	(2.31)	(3.03)	(2.34)	(0.97)	(0.15)	(0.15)	(0.10)		(8.3%)
	Capex	0.00	0.00	0.00	0.00	0.00	(0.01)	(0.04)	0.00	0.00	0.00	0.00		n/m
	Free cash flow	(0.32)	(1.25)	(0.78)	(1.79)	(2.31)	(3.04)	(2.37)	(0.97)	(0.15)	(0.15)	(0.10)		(8.3%)
	Book value	(0.59)	(1.48)	(4.60)	(0.07)	1.35	3.54	1.02	0.29	0.06	0.66	0.47		n/m
	Shares, m	11	1	1	2	2	3	3	4	12	20	24		+7.2%
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	0.00		0.0
	P/S	—	—	63,310.91	108.98	208.14	240.96	19.78	34.40	13.74	—	19.38		9,133.8
	P/B	—	—	0.00	0.00	37.77	9.67	5.93	4.19	9.67	—	2.06		9.6
	EV/Sales	—	—	63,320.35	109.75	208.79	228.64	22.08	51.34	15.33	—	20.64		9,136.6
	EV/FCF	—	—	(464.09)	(24.57)	(22.10)	(10.68)	(2.85)	(1.86)	(4.26)	—	(9.91)		(75.8)
Cash, $m
Cash, $m	Operating cash flow	(3)	(1)	(1)	(3)	(5)	(8)	(7)	(4)	(2)	(3)	(3)		(1.7%)
	Capex	—	—	—	—	—	0	0	0	—	—	0		+10.1%
	Free cash flow	(3)	(1)	(1)	(3)	(5)	(8)	(8)	(4)	(2)	(3)	(3)		(1.7%)
Balance, $m
Balance, $m	Working capital	(6)	(2)	(10)	(6)	1	4	(3)	(4)	(4)	(4)	(5)		(6.0%)
	Net debt	0	1	0	0	(2)	(7)	(1)	(1)	(1)	(1)	0		+26.0%
	Shareholders’ equity	(6)	(2)	(5)	0	3	9	3	1	1	13	12		n/m
Returns, %
Returns, %	ROA	(6,205.02)	(157.20)	(129.91)	(56.60)	(105.65)	(101.47)	(141.11)	(89.70)	(63.99)	(55.30)	(39.88)		+6,149.7 pt
	ROIC	0.00	0.00	0.00	0.00	(1,864.65)	(333.03)	(534.12)	(924.61)	0.00	(37.54)	(33.45)		(37.5) pt
	ROE	172.56	269.39	157.11	133.27	(771.78)	(222.66)	(271.31)	(346.94)	(495.87)	(112.81)	(65.32)		(285.4) pt
People
People	Employees	9	9	38	5	34	30	23	19	19	19	—		+8.7%
	Revenue/emp, $m	0.00	0.00	0.00	0.14	0.01	0.01	0.04	0.01	0.03	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Sep 2025 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ALGS Aligos Therapeutics, Inc.	$28.2M	— (loss-making)	— (loss-making)	+287.18% (above 0%: growing)	n/m	+105.91% (above 0%: growing)	100.00%	(762.98%)	Compare
MGX Metagenomi Therapeutics, Inc.	$27.6M	— (loss-making)	— (loss-making)	−103.02% (below 0%: shrinking)	n/m	+7.98% (above 0%: growing)	100.00%	11,195.72%	Compare
PLRZ Polyrizon Ltd.	$27.5M	—	—	—	—	−744.51% (below 0%: shrinking)	—	—	Compare
ACET Adicet Bio, Inc.	$27.3M	— (loss-making)	— (loss-making)	+727.73% (above 0%: growing)	n/m	+24.94% (above 0%: growing)	0.00%	0.00%	Compare
BYSI BeyondSpring Inc.	$26.0M	— (loss-making)	— (loss-making)	+87.78% (above 0%: growing)	n/m	+35.78% (above 0%: growing)	100.00%	0.00%	Compare
ABVC ABVC BioPharma, Inc.	$25.9M	— (loss-making)	— (loss-making)	+66,233.33% (above 0%: growing)	n/m	+72.66% (above 0%: growing)	100.00%	0.00%
RNAZ TransCode Therapeutics Inc.	$25.6M	— (loss-making)	—	—	n/m	−28.79% (below 0%: shrinking)	0.00%	0.00%	Compare
AARD Aardvark Therapeutics, Inc.	$24.3M	— (loss-making)	—	—	n/m	−77.14% (below 0%: shrinking)	—	0.00%	Compare
CVM Cel-Sci Corporation	$24.1M	— (loss-making)	— (loss-making)	−62.66% (below 0%: shrinking)	n/m	−2.33% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$26.7M	—	—	+87.78%	—	+2.82%	50.00%	0.00%

All 621 Biotechnology stocks →

ABVC BioPharma, Inc. (ABVC) Latest News

23 Jun

Impact 4 · 8:30 AM · NewMediaWire

ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders

24 Feb

Impact 3 · 8:30 AM

ABVC BioPharma Provides Corporate and Structural Update

2 Dec

Impact 4 · 8:30 AM · NewMediaWire

ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States

26 Nov

Impact 4 · 8:30 AM · NewMediaWire

ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030

21 Nov

Impact 4 · 8:30 AM · NewMediaWire

ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received

18 Nov

Impact 3 · 8:30 AM · NewMediaWire

ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million

3 Nov

Impact 4 · 8:00 AM

ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025

17 Oct

Impact 4 · 7:30 AM · NewMediaWire

ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology

8 Oct

Impact 3 · 7:30 AM · NewMediaWire

ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production

23 Sep

Impact 4 · 7:11 PM · Insider MonkeyInsider MonkeyInsider MonkeyInsider MonkeyInsider Monkey

ABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression Therapies

19 Sep

Impact 4 · 7:30 AM

ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model

27 Aug

Impact 3 · 2:25 AM · NewMediaWireBankrateSmartAsset

BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration

22 Aug

Impact 3 · 7:30 AM

ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing Deal

14 Aug

Impact 4 · 7:30 AM · NewMediaWire

ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025

8 Aug

Impact 4 · 7:00 AM · NewMediaWire

BioKey Stands as a Strategic U.S. Pharmaceutical Platform Amid Global Tariff Shifts

6 Aug

Impact 4 · 7:30 AM · NewMediaWire

ABVC BioPharma Gains Confidence From International Investors to Support Growth Path

1 Aug

Impact 4 · 7:00 AM · NewMediaWire

OncoX Deepens ABVC Alliance

24 Jul

Impact 3 · 9:00 AM

ABVC BioPharma Strengthens Oncology Partnership With $100,000 Milestone Payment From OncoX BioPharma

18 Jul

Impact 3 · 9:00 AM

ABVC BioPharma Records $100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program

10 Jul

Impact 4 · 5:32 PM · NewMediaWire

ABVC BioPharma Receives $150K Milestone From AiBtl, Bringing Total Licensing Revenue to $846K Across Strategic Partnerships

26 Jun

Impact 4 · 8:00 AM · NewMediaWire

ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology

24 Jun

Impact 4 · 8:00 AM · NewMediaWire

ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment

6 Jun

Impact 4 · 8:30 AM · NewMediaWire

ABVC BioPharma Expands Oncology Portfolio as Affiliate OncoX Acquires Patented Lycopenoid Platform Valued at $4.06 Million

3 Jun

Impact 4 · 6:00 AM

ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value

14 May

Impact 3 · 9:00 AM

ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance

9 May

Impact 4 · 9:00 AM · NewMediaWire

ABVC BioPharma Secures Japanese Patent for Its Natural MDD Treatment Candidate ABV-1504

1 May

Impact 4 · 8:30 AM · NewMediaWire

ABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan

16 Apr

Impact 3 · 9:00 AM

UPDATE: ABVC BioPharma Announces 2024 Financial Results

15 Apr

Impact 4 · 4:30 PM

ABVC BioPharma Announces 2024 Financial Results

3 Apr

Impact 4 · 9:00 AM · NewMediaWire

ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

ABVC BioPharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

ABVC BioPharma, Inc. (ABVC) Latest News

23 Jun

24 Feb

2 Dec

26 Nov

21 Nov

18 Nov

3 Nov

17 Oct

8 Oct

23 Sep

19 Sep

27 Aug

22 Aug

14 Aug

8 Aug

6 Aug

1 Aug

24 Jul

18 Jul

10 Jul

26 Jun

24 Jun

6 Jun

3 Jun

14 May

9 May

1 May

16 Apr

15 Apr

3 Apr

Stockrow Weekly